Lifecore Biomedical (LFCR) investor relations material

Business transformation and strategic focus

• Completed divestiture of food businesses in 2022–2023, now focused solely on life sciences.

• Operates two main segments: hyaluronic acid fermentation for sterile injectables and contract manufacturing for sterile injectable products.

• CEO with 35 years in pharma and 32 in CDMO, joined to leverage existing capacity and quality for growth.

• Shifted business development from a farming to a hunting approach, targeting new modalities and markets, including biologics.

• No plans to expand sales headcount; leveraging digital tools and partnerships for broader reach.

Financial outlook and operational targets

• Reinforced mid-term revenue guidance to $212–$225 million, with a 12% CAGR from 2025–2029.

• EBITDA margin target increased from 15% to over 25% by 2029, with progress to 17% during the transition period.

• Capacity utilization expected to rise from 20% today to 60% by 2029, with potential for further expansion at 80%.

• Over $10 million in free cash flow projected for 2026, with cost initiatives providing potential upside.

• Major cost initiatives underway, including a new head of business transformation and successful ERP system launch.

Growth drivers and pipeline development

• Largest customer expected to more than double fill-finish demand by 2029.

• Ten late-stage programs in pipeline, with a 50% conversion rate anticipated to drive commercialization.

• Two recent tech transfer agreements could each become top five customers, targeting commercial launch in 2028 with $10M+ annual revenue potential.

• Significant number of additional tech transfer opportunities in the pipeline, with more wins expected by end of 2025.

• GLP-1 market participation not essential for success, but current program could be meaningful if approved by 2029.